Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of ...
The company ended the third quarter of 2025 with $715 million in cash, a war chest deemed sufficient to fund both ongoing VANQUISH trials to completion. Research and development expenses jumped to $90 ...
No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback